Free Trial

Rapt Therapeutics (RAPT) Competitors

Rapt Therapeutics logo
$8.62 +0.18 (+2.13%)
Closing price 07/10/2025 04:00 PM Eastern
Extended Trading
$8.62 0.00 (-0.06%)
As of 07/10/2025 04:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

RAPT vs. OPT, MGTX, TYRA, BCAX, KURA, TSHA, MNMD, ABVX, VALN, and ZVRA

Should you be buying Rapt Therapeutics stock or one of its competitors? The main competitors of Rapt Therapeutics include Opthea (OPT), MeiraGTx (MGTX), Tyra Biosciences (TYRA), Bicara Therapeutics (BCAX), Kura Oncology (KURA), Taysha Gene Therapies (TSHA), Mind Medicine (MindMed) (MNMD), Abivax (ABVX), Valneva (VALN), and Zevra Therapeutics (ZVRA). These companies are all part of the "pharmaceutical products" industry.

Rapt Therapeutics vs. Its Competitors

Opthea (NASDAQ:OPT) and Rapt Therapeutics (NASDAQ:RAPT) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, risk, institutional ownership, valuation, analyst recommendations, dividends and media sentiment.

56.0% of Opthea shares are held by institutional investors. Comparatively, 99.1% of Rapt Therapeutics shares are held by institutional investors. 3.2% of Opthea shares are held by company insiders. Comparatively, 2.4% of Rapt Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Rapt Therapeutics has higher revenue and earnings than Opthea.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Opthea$120K4,373.61-$220.24MN/AN/A
Rapt Therapeutics$1.53M93.19-$129.87M-$19.20-0.45

Opthea presently has a consensus target price of $1.33, suggesting a potential downside of 60.90%. Rapt Therapeutics has a consensus target price of $19.80, suggesting a potential upside of 129.70%. Given Rapt Therapeutics' higher probable upside, analysts clearly believe Rapt Therapeutics is more favorable than Opthea.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Opthea
1 Sell rating(s)
4 Hold rating(s)
0 Buy rating(s)
1 Strong Buy rating(s)
2.17
Rapt Therapeutics
1 Sell rating(s)
3 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.17

In the previous week, Rapt Therapeutics had 3 more articles in the media than Opthea. MarketBeat recorded 4 mentions for Rapt Therapeutics and 1 mentions for Opthea. Rapt Therapeutics' average media sentiment score of 0.78 beat Opthea's score of 0.55 indicating that Rapt Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
Opthea Positive
Rapt Therapeutics Positive

Opthea's return on equity of 0.00% beat Rapt Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
OptheaN/A N/A N/A
Rapt Therapeutics N/A -81.47%-70.24%

Opthea has a beta of 1.17, meaning that its share price is 17% more volatile than the S&P 500. Comparatively, Rapt Therapeutics has a beta of -0.09, meaning that its share price is 109% less volatile than the S&P 500.

Summary

Rapt Therapeutics beats Opthea on 7 of the 13 factors compared between the two stocks.

Get Rapt Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for RAPT and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RAPT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

RAPT vs. The Competition

MetricRapt TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$139.57M$2.96B$5.55B$9.03B
Dividend YieldN/A2.43%5.25%4.04%
P/E Ratio-0.4521.1127.2020.14
Price / Sales93.19251.53413.1198.19
Price / CashN/A42.7337.5058.41
Price / Book0.757.748.085.60
Net Income-$129.87M-$54.96M$3.16B$248.43M
7 Day Performance6.09%9.10%4.70%5.47%
1 Month Performance-2.05%5.73%4.50%7.87%
1 Year Performance-69.04%2.79%31.01%18.75%

Rapt Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
RAPT
Rapt Therapeutics
4.4177 of 5 stars
$8.62
+2.1%
$19.80
+129.7%
-67.9%$139.57M$1.53M-0.4580Analyst Forecast
OPT
Opthea
0.3212 of 5 stars
$3.41
+7.2%
$1.33
-60.9%
+72.6%$524.83M$120K0.008Gap Up
MGTX
MeiraGTx
4.4444 of 5 stars
$6.52
-1.4%
$24.00
+268.1%
+108.2%$523.95M$33.28M-2.81300Insider Trade
TYRA
Tyra Biosciences
1.891 of 5 stars
$9.57
+5.2%
$30.83
+222.2%
-43.5%$508.07MN/A-5.8720
BCAX
Bicara Therapeutics
1.4398 of 5 stars
$9.29
+6.7%
$31.86
+242.9%
N/A$506.68MN/A0.0032
KURA
Kura Oncology
4.5609 of 5 stars
$5.77
+1.8%
$24.50
+324.6%
-68.7%$499.54M$67.99M-2.75130
TSHA
Taysha Gene Therapies
2.7366 of 5 stars
$2.31
-2.9%
$8.00
+246.3%
+12.8%$495.87M$8.33M-6.79180
MNMD
Mind Medicine (MindMed)
3.0059 of 5 stars
$6.49
-0.9%
$25.50
+292.9%
+14.1%$490.32MN/A-5.0340Positive News
ABVX
Abivax
2.6182 of 5 stars
$7.65
+3.4%
$31.00
+305.2%
-37.1%$485.39MN/A0.0061Positive News
Gap Up
High Trading Volume
VALN
Valneva
1.534 of 5 stars
$5.67
-2.2%
$15.50
+173.4%
-16.3%$482.46M$183.52M-4.76700
ZVRA
Zevra Therapeutics
2.8005 of 5 stars
$8.81
-2.1%
$22.29
+153.0%
+113.9%$481.73M$23.61M-4.6420News Coverage
Analyst Forecast
Gap Up

Related Companies and Tools


This page (NASDAQ:RAPT) was last updated on 7/11/2025 by MarketBeat.com Staff
From Our Partners